Publications by authors named "Jose Maria Velarde"

Claim this Profile
E
Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution.
Sofia España, Alejandra Pérez Montes de Oca, Montserrat Marques-Pamies, Marc Cucurull, Marta Domenech, José María Velarde

Transl Lung Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of stem cell markers in glioblastoma.
Francesc Alameda, José María Velarde, Cristina Carrato, Noemí Vidal, Montserrat Arumí

Biomarkers· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients.
Max Hardy-Werbin, Vanesa Quiroga, Beatriz Cirauqui, Margarita Romeo, Eudald Felip, Jose Maria Velarde

Sci Rep· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer.
Teresa Moran, Vanesa Quiroga, Beatriz Cirauqui, Laia Vila, Maria Gil-Moreno, Jose Maria Velarde

Oncol Res Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients.
Anna Estival, Carolina Sanz, Jose-Luis Ramirez, Jose Maria Velarde, Marta Domenech

Sci Rep· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Monitoring -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Teresa Morán, Eudald Felip, Joaquim Bosch-Barrera, Itziar de Aguirre, Jose Luis Ramirez, Jose María Velarde

Oncotarget· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Teresa Morán, Eudald Felip, Joaquim Bosch-Barrera, Itziar de Aguirre, Jose Luis Ramirez, Jose María Velarde

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.
Jaume Capellades, Josep Puig, Sira Domenech, Teresa Pujol, Laura Oleaga, Jose Maria Velarde

J Neurooncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudoprogression as an adverse event of glioblastoma therapy.
Carmen Balaña, Jaume Capellades, Estela Pineda, Anna Estival, Josep Puig, JoseMaria Velarde

Cancer Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis